Skip to main content
. 2023 Feb 7;3:14. doi: 10.1038/s43856-023-00243-7

Fig. 3. Confirmation of the predictive nature of the immunotherapy response score (IRS) biomarker.

Fig. 3

To establish the predictive nature of the IRS model, we assessed an internal comparator in the pembrolizumab monotherapy cohort, consisting of the 146 patients who had received a prior line of systemic therapy prior to pembrolizumab monotherapy (n = 146 individual patients). a For each patient, real-world progression-free survival (rwPFS) was determined for the line of systemic therapy immediately prior to pembrolizumab (pembro; yellow) and the pembrolizumab monotherapy line (purple), with rwPFS for each group then stratified by IRS status. b Kaplan–Meier analysis of pembrolizumab monotherapy rwPFS (purple) vs. prior systemic therapy rwPFS (yellow) in the IRS-Low [L] subset of patients (log-rank p-value shown). The number (n) of patients, events, and median rwPFS (with 95% confidence intervals [CI]) for each group are shown. c Kaplan–Meier analysis of pembrolizumab monotherapy rwPFS (purple) vs. prior systemic therapy rwPFS (yellow) in the IRS-H subset of patients (log-rank p-value shown). The likelihood ratio test (LRT) p-value for interaction between pembrolizumab vs. immediately prior treatment line and IRS status (IRS-L vs. IRS-High [H]) is also shown.